

Substrates for TAFIa

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a U.S. National Phase Application of PCT/CH02/000670,
5 filed December 6, 2002, which claims priority to PCT/CH02/00553, filed October 4,
2002, the contents all of which are incorporated herein by reference.

TAFI (thrombin-activatable fibrinolysis inhibitor) is a carboxypeptidase B-like
proenzyme of 55 kDa that is activated into the enzyme TAFIa (35 kDa) by proteolysis
10 at Arg-92. Conversely to carboxypeptidase B which is activated as a proenzyme of 46
kDa by proteolysis at Arg-95 and which is active in the stomach and digestive tract,
TAFIa is a liver enzyme that is efficient in blood.

TAFIa is formed from TAFI by thrombin and probably also plasmin, and constitutes an
15 important inhibitor of fibrinolysis. Binding of thrombin to thrombomodulin strengthens
the activation of TAFI by approx. 1250. The inhibiting effect of TAFIa bases on the
capacity to split off carboxy-terminal arginines and lysines, the specificity towards
arginine being higher.

20 TAFIa itself is very sensitive to proteolyses and instable already at 37°C.

Fibrinolysis begins with the conversion of plasminogen into plasmin by tPA. Afterwards,
plasmin decomposes the fibrin clot into soluble fibrin products which themselves
contribute to further stimulate plasmin formation. TAFIa splits off the carboxy-terminal
25 lysines of these fibrin products, which prevents the formation of the
tPA/plasminogen/fibrin complex, thereby inhibiting the fibrinolysis.

Measuring the TAFIa concentration in plasma is very useful to evaluate the bleeding
and thrombosis risk of patients.

30

A determination of carboxypeptidases using immunological tests, such as ELISA for
example, is possible, but these tests do not consider the activity of TAFI. Functional
tests are described, wherein TAFIa acts on synthetic substrates of the R-Arg-COOH or
R-Lys-COOH type, thereby releasing 'R' (e.g. hippuryl) that can be measured by HPLC
35 or spectrophotometry in the near UV range.


5

The thiaarginine derivatives of the following formulas A and B




15

Fig. Scheme 1



Surprisingly, this selectivity can be changed in favour of TAFIa already by minor structure variations.

25 The present invention relates to new TAFIa substrates of the general formula I



30 wherein

R_1 means a CH_2NH_2 or NHC(NH)NH_2 group,

AA_2 means non-substituted or substituted lysine, ornithine, arginine or histidine, wherein the substituents are common protective groups,

AA₃ means a natural amino acid in which a present, protectable group may be substituted with a usual protective group in the side chain,

n represents 0 or 1, and

R₂ means a Bz, Bzl, Ac, Boc, Z, Suc, MeoSuc or Tos group,

- 5 provided that the following cases do not occur simultaneously: n = 0, R₁ = NHC(NH)NH₂, R₂ = Z and (AA₂) = non-substituted or Boc-substituted lysine, as racemates or enantiomeric pure isomers, and the salts thereof with mineral or organic acids.

- 10 R₁ preferably means NHC(NH)NH₂.

The preferred denotations of AA₂ may be e.g. Lys(ε-Z), Lys(ε-Boc), Lys(ε-Ac), Lys(ε-Bz), Lys(ε-Bzl), Lys(ε-Tos), Orn(δ-Z), Orn(δ-Boc), Orn(δ-2-chlor-Z), Orn(δ-Dnp), Orn(δ-Z), Orn(δ-Aloc), Arg(ω-Pbf), Arg(δ,ω-Boc)₂, Arg(δ,ω-Z)₂, Arg(ω-Tos), His(N^{im}-Boc),
15 His(N^{im}-Ac), His(N^{im}-Bz), His(N^{im}-Bzl) or His(N^{im}-Tos), Lys(ε-Z) being particularly preferred.

E.g. tBu, Bzl or Ac can be taken into account as protective groups in the amino acid AA₃, wherein phenylalanine, alanine, serine and valine are preferred amino acids.

20

R₂ preferably means Bz or Boc.

E.g. hydrobromides, hydrochlorides, trifluoroacetates or acetates can be taken into account as salts, wherein acetate, trifluoroacetate and hydrochloride salts are preferred.

25

The above used abbreviations for protective groups as well as a series of further abbreviations are explained in the table to be found between Example 2 and Example 3.

- 30 The compounds of general formula I, which - relating to the asymmetrical carbon with the sulfur-containing substituent - can be present as racemates or in one of their enantiomer-pure configurations D and L, can be manufactured according to the known methods described hereinafter.

Protected amino acids or protected oligopeptide derivatives are converted into the corresponding acid amides, and these are condensed under reflux with an alkyl ester of glyoxylic acid, preferably a C₁₋₆ alkyl ester such as ethyl glyoxylate, according to the method described by Hong, N.J. et al., Bull. Korean Chem. Soc. 1998, 19(2), 189-193.

- 5 The thereby resulting hydroxyglycine derivatives are O-acetylated and substituted with a corresponding mercaptoalkyl compound, such as cystamine, 3-mercaptopropylamine or S-2-aminoethylisothiuronium bromide. Afterwards, the obtained alkylesters of the compounds of formula I are saponified into the corresponding free acids. The enantiomer-pure acids can be obtained through enantioselective hydrolysis of the
10 esters by means of appropriate enzymes.

- The compounds of formula I and their acid addition salts are appropriate substrates for the determination of TAFIa. According to the present invention, the determination can be performed by reacting TAFIa in the presence of 5,5'-dithiobis-(2-nitrobenzoic acid),
15 the so-called "Ellman's Reagent", on a compound according to one of claims 1 to 7 and measuring the absorption between 400 and 412 nm resulting from the formation of 3-carboxy-4-nitrothiophenol as a function of time using a spectrophotometer. The mentioned reaction preferably takes place between approx. 10°C and 37°C, preferably at room temperature, and the reaction period may last approx. 5 to 15 minutes,
20 preferably about 10 minutes. TAFI present in blood plasma can be used as the source of TAFIa.

- The following examples are intended to further explain the present invention without limiting its scope.

25

The eluates and products obtained according to Examples 1 and 2 were identified and characterized by proton NMR, HPLC electrospray MS and/or elementary analysis.

Example 1:

- 30 Preparation of benzoyl-(L)-lysyl-(ε-benzoyloxycarbonyl)-α-(D,L)-(2-guanidinoethylthio)-glycine hydrochloride salt [Bz-(L)-Lys(Z)-(D,L)-Gly(α-GUS)-OH • HCl]

1A) Benzoyl-(L)-lysyl(ϵ -benzyloxycarbonyl)- α -(D,L)-hydroxyglycine-ethylester[Bz-(L)-Lys(Z)-(D,L)-Gly(α -OH)-Oet]

5.0 g (13 mmol) of benzoyl-(L)-lysine amide and a 50% toluene solution of 13.3 g (65 mmol) of ethyl glyoxylate were refluxed in 100 ml of THF. After 4 hours, the solution
5 was cooled to RT and directly converted in the reaction step 1B).

1B) Benzoyl-(L)-lysyl(ϵ -benzyloxycarbonyl)- α -(D,L)-acetoxglycine-ethylester[Bz-(L)-Lys(Z)-(D,L)-Gly(α -Oac)-Oet]

The reaction solution from 1A) was mixed with 127 mg (1 mmol) of DMAP, 24.7 ml
10 (0.31 mol) of pyridine and 40 g (0.39 mol) of acetic acid anhydride and stirred for 90 min. at RT. The reaction solution was filtered over silica gel, the solvent was evaporated and the obtained raw product was dried in a vacuum desiccator.

Yield: 14 g.

15 1C) Benzoyl-(L)-lysyl(ϵ -benzyloxycarbonyl)- α -(D,L)-(2-guanidinoethylthio)-glycineethylester [Bz-(L)-Lys(Z)-(D,L)-Gly(α -GUS)-OEt]

5.5 g (19.5 mmol) of S-(2-aminoethyl)isothiuronium bromide hydrobromide and 4 g
(39 mmol) of TEA were dissolved in 50 ml of DMF and stirred for 5 min. at RT. Afterwards, a solution of 14 g of the product obtained under 1B) in 30 ml of DMF was
20 added. After 2 hours of stirring at RT, the solvent was evaporated on a rotovapor. The obtained raw material was chromatographed with LH20 (methanol). The compound precipitated as a yellowish oil.

ESI-MS [M+H]⁺– 587

25 1D) Benzoyl-(L)-lysyl(ϵ -benzyloxycarbonyl)- α -(D,L)-(2-guanidinoethylthio)-glycinehydrochloride salt [Bz-(L)-Lys(Z)-(D,L)-Gly(α -GUS)-OH • HCl]

3.1 g (4.4 mmol) of compound 1C) was dissolved in 20 ml of ethanol, mixed with 11 ml
of NaOH (1N) and stirred overnight at RT. After adjustment of the pH to 3 with citric
30 acid and evaporation of the solvent, the residue was chromatographed with LH20 (methanol). For conversion into the hydrochloride salt, the pure, concentrated fractions are dissolved in 100 ml of a methanol/water mixture (1:1) and chromatographed over Amberlite (Cl⁻ form). The obtained solution was concentrated on the rotovapor and the

product precipitated as a nearly white, amorphous powder under addition of BME. The powder was filtered off, washed with some BME and dried in a vacuum drier.

Yield: 2.5 g, ESI-MS [M+H]⁺ – 559

5 Example 2:

Preparation of benzoyl-(L)-lysyl-(ε-benzyloxycarbonyl)-α-(D,L)-(3-aminopropylthio)-glycine trifluoroacetic acid salt [Bz-(L)-Lys(Z)-(D,L)-Gly(α-SprA)-OH • TFA]

2C) Benzoyl-(L)-lysyl-(ε-benzyloxycarbonyl)-α-(D,L)-(3-aminopropylthio)-glycine ethylester trifluoroacetic acid salt [Bz-(L)-Lys(Z)-(D,L)-Gly(α-SprA)-Oet • TFA]
 10 2.5 g (20 mmol) of 3-mercaptopropylamine hydrochloride and 2 g (20 mmol) of TEA were dissolved in 40 ml of DMF, the solution was stirred for 5 min at RT and added to a solution of 6.9 g of the product obtained under 1B) in 30 ml of DMF. After 2 hours of stirring at RT, the solvent was evaporated on a rotovapor. The obtained raw material
 15 was chromatographed by preparative HPLC (ACN/H₂O/TFA). The pure fractions were concentrated on the rotovapor.

ESI-MS [M+H]⁺ – 559

2D) Benzoyl-(L)-lysyl-(ε-benzyloxycarbonyl)-α-(D,L)-(3-aminopropylthio)-glycine trifluoroacetic acid salt [Bz-(L)-Lys(Z)-(D,L)-Gly(α-SprA)-OH • TFA]
 20 0.43 g (0.6 mmol) of compound 2C) was dissolved in 7 ml of ethanol, mixed with 2 ml of NaOH (1N) and stirred overnight at RT. The reaction solution was adjusted to pH 3 with citric acid 10%, extracted 3 times with 20 ml of ethylacetate and washed twice with saturated NaCl solution. The organic phase was dried over Na₂SO₄, filtered and the
 25 solvent was evaporated on the rotovapor. The raw material was chromatographed by preparative HPLC (ACN/H₂O/TFA). The pure fractions were concentrated on the rotovapor, whereupon the residue was dissolved in some methanol and precipitated by addition of BME. The nearly white powder was filtered off, washed with some BME and dried in a vacuum desiccator.

30 ESI-MS [M+H]⁺ – 531

Abbreviations

Ac	Acetyl
ACN	Acetonitrile
Aloc	Allyloxycarbonyl
BME	t-Butyl methyl ether
Boc	t-Butyloxycarbonyl
Bz	Benzoyl
Bzl	Benzyl
DMAP	4-(Dimethylamino)-pyridine
DMF	N,N-Dimethylformamide
Dnp	2,4-Dinitrophenyl
DTNB	5,5'-Dithiobis-(2-nitrobenzoic acid)
EtOAc	Ethylacetate
GUS	2-Guanidino-ethylthio
HEPES	4-(2-Hydroxyethyl)-piperazin-1-ethane sulfonic acid
LH20	Sephadex
MeoSuc	Methoxysuccinyl
NAPAP	N α -(2-naphthylsulfonyl-glycyl)-4-amidinophenylalanine piperidide
Pbf	2,2,4,6,7-Pentamethyl-dibenzohydrofuran-5-sulfonyl
SprA	3-Aminopropylthio
RT	Room temperature
Suc	Succinyl
tBu	tert.-Butyl
TEA	Triethylamine
TFA	Trifluoroacetic acid
THF	Tetrahydrofuran
Tos	Tosyl
Z	Benzyloxycarbonyl

Example 3:

- 5 Quantitative determination of TAFIa

Principle: TAFIa is determined as shown in Scheme Fig. 1. In a first step, the substrate is hydrolyzed by TAFIa in such a way that a thioamino acid (thiaarginine or thialysine) is released. These instable intermediates are rapidly decomposed into 2-mercaptoethylguanidine or 3-mercaptopropylamine, respectively. These mercapto compounds react with Ellman's reagent (5,5'-dithio-bis-(2-nitrobenzoic acid)), thereby releasing the strongly yellow 3-carboxy-4-nitrothiophenol that can be measured using a spectrophotometer at 405-412 nm. The free thiol content measured is directly proportional to the quantity of substrate hydrolyzed by TAFIa and thereby allows a quantitative analysis of the enzyme activity.

Enzyme assay: The enzyme activity is measured at room temperature by using a 10 mM substrate stock solution in DMSO. TAFI of human origin can be obtained in a stock solution of 360 µg/ml from Enzyme Research Laboratory or over blood plasma. Activation of TAFI to TAFIa occurred with thrombin (2.7 U/ml), the activation of which was produced with 30 µg of thrombomodulin. Excessive thrombin activity was eliminated by adding the synthetic inhibitor NAPAP. The measurement was performed on microtiter plates.

The absorption increase at 405-412 nm was recorded for 10 minutes.

Activation:

TAFI	20	µl
Thrombin (2.7 U/ml)	20	µl
Thrombomodulin (30 µg/ml)	20	µl

in buffer (20 mM HEPES, 5 mM CaCl₂, 0.01% Tween 80; pH 7.4)

incubate for 5 min at 25°C

Measurement:

Buffer (20 mM HEPES, 5 mM CaCl ₂ , 0.01% Tween 80; pH 7.4)	120	µl
NAPAP (100 µM)	20	µl
DTNB (5 mM)	10	µl
Substrate (10 mM)	20	µl

measure for 10 min at RT

Results:


- Splitting of thiaarginine and thialysine substrates (final concentration 174 μ M) by TAF1a (final concentration 17 μ g/ml)
- in brackets the value for carboxypeptidase B
- Substances of comparison A and B from Bull. Korean. Chem. Soc. 1998, 19(2), 189-193
- ΔE = Extinction variation at 405 nm

Table 1

No.	Substrate	$\Delta E/\text{min}$	
4269	Bz-K(Z)-G(GUS)-OH x HCl	0.108	(0.018)
4273	Boc-K(Tos)-G(GUS)-OH x HCl	0.014	(0.048)
4275	Boc-K(Z)-G(GUS)-OH x TFA	0.041	(0.028)
4298	Boc-F-K(Boc)-G(GUS)-OH x HCl	0.043	(0.034)
4300	Bz-P-K(Boc)-G(GUS)-OH x TFA	0.012	(0.072)
4302	Z-A-K(Boc)-G(GUS)-OH x HCl	0.042	(0.059)
4334	Bz-V-G(GUS)-OH x TFA	0.034	
4336	Bz-V-G(α -SPrA)-OH x TFA	0.053	
4339	Bz-K(Z)-G(α -SPrA)-OH x TFA	0.055	
4341	Boc-K(Z)-G(α -SPrA)-OH x TFA	0.054	
	Substance of comparison A x HCl	0.002	(0.062)
	Substance of comparison B x HCl	0.016	(0.077)

Claims

1. (Previously presented) Compounds of general formula I



- 5 wherein

R₁ means a CH₂NH₂ or NHC(NH)NH₂ group,

AA₂ means non-substituted or substituted L-lysine, wherein the substituents are common protective groups, and

R₂ means a Bz, Bzl, Ac, Boc, Z, Suc, MeoSuc or Tos group,

- 10 provided that the following cases do not occur simultaneously: R₁ = NHC(NH)NH₂, R₂ = Z and (AA₂) = non-substituted or Boc-substituted L-lysine,

and the salts thereof with mineral or organic acids.

- 15 2. (Previously presented) Compounds according to claim 1, wherein AA₂ represents L-Lys(ε-Z), L-Lys(ε-Boc), L-Lys(ε-Ac), L-Lys(ε-Bz), L-Lys(ε-Bzl), L-Lys(ε-Tos), or L-Lys(ε-Z).

- 3.-4. (Previously cancelled)

20

5. (Currently amended) Compounds according to claim 1, wherein

R₁ means NHC(NH)NH₂,

AA₂ means L-Lys(ε-Z) or L-Lys(ε-Boc), and

R₂ ~~represents~~ means Bz, Boc or Z.

25

6. (Currently amended) Compounds according to claim 1, wherein

R₁ means CH₂NH₂,

AA₂ means L-Lys(ε-Z) or L-Lys(ε-Boc), and

R₂ ~~represents~~ means Bz, Boc or Z.

30

7. (Currently amended) Compounds according to claim 1, wherein the compounds
~~thereby characterized that they~~ are present as acid addition salts in the form of
hydrobromides, hydrochlorides, trifluoroacetates or acetates.

5 8.-14. (Previously cancelled)

15. (Previously presented) Compounds according to claim 2, wherein the
compounds are present as acid addition salts in the form of hydrobromides,
hydrochlorides, trifluoroacetates or acetates.

10

16.-19. (Previously cancelled)

Abstract

The invention relates to compounds of general formula (I) and acid addition salts thereof, where the various symbols have the meanings given in the description and claims, the production and use thereof as substrate for the detection of TAFIa, a
5 fibrinolysis inhibiting enzyme. The detection occurs by using the absorption between 400 and 412 nm, arising as a result of the formation of 3-carboxy-4-nitrothiophenol from Ellman's reagent as a function of time.